| Trefts E, Gannon M, Wasserman D H. The liver[J]. Current Biology, 2017, 27(21):R1147-R1151 |
| Ortega-Alonso A, Andrade R J. Chronic liver injury induced by drugs and toxins[J]. Journal of Digestive Diseases, 2018, 19(9):514-521 |
| Tabernilla A, dos Santos Rodrigues B, Pieters A, et al. In vitro liver toxicity testing of chemicals:A pragmatic approach[J]. International Journal of Molecular Sciences, 2021, 22(9):5038 |
| Sabljic A. Chemical topology and ecotoxicology[J]. The Science of the Total Environment, 1991, 109-110:197-220 |
| Treyer A, Müsch A. Hepatocyte polarity[J]. Comprehensive Physiology, 2013, 3(1):243-287 |
| Lauschke V M, Hendriks D F, Bell C C, et al. Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates[J]. Chemical Research in Toxicology, 2016, 29(12):1936-1955 |
| Pampaloni F, Reynaud E G, Stelzer E H K. The third dimension bridges the gap between cell culture and live tissue[J]. Nature Reviews Molecular Cell Biology, 2007, 8(10):839-845 |
| Ide I, Nagao, Kajiyama S, et al. A novel evaluation method for determining drug-induced hepatotoxicity using 3D bio-printed human liver tissue[J]. Toxicology Mechanisms and Methods, 2020, 30(3):189-196 |
| Lee D W, Oh W Y, Yi S H, et al. Estimation of bisphenol A:Human toxicity by 3D cell culture arrays, high throughput alternatives to animal tests[J]. Toxicology Letters, 2016, 259:87-94 |
| Leist M, Ghallab A, Graepel R, et al. Adverse outcome pathways:Opportunities, limitations and open questions[J]. Archives of Toxicology, 2017, 91(11):3477-3505 |
| Horvat T, Landesmann B, Lostia A, et al. Adverse outcome pathway development from protein alkylation to liver fibrosis[J]. Archives of Toxicology, 2017, 91(4):1523-1543 |
| de Bruyn T, Chatterjee S, Fattah S, et al. Sandwich-cultured hepatocytes:Utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity[J]. Expert Opinion on Drug Metabolism&Toxicology, 2013, 9(5):589-616 |
| Ramaiahgari S C, den Braver M W, Herpers B, et al. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies[J]. Archives of Toxicology, 2014, 88(5):1083-1095 |
| Palakkan A A, Raj D K, Rojan J, et al. Evaluation of polypropylene hollow-fiber prototype bioreactor for bioartificial liver[J]. Tissue Engineering Part A, 2013, 19(9-10):1056-1066 |
| Choe A, Ha S K, Choi I, et al. Microfluidic gut-liver chip for reproducing the first pass metabolism[J]. Biomedical Microdevices, 2017, 19(1):4 |
| Mazzocchi A, Soker S, Skardal A. 3D bioprinting for high-throughput screening:Drug screening, disease modeling, and precision medicine applications[J]. Applied Physics Reviews, 2019, 6(1):011302 |
| Deharde D, Schneider C, Hiller T, et al. Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition[J]. Archives of Toxicology, 2016, 90(10):2497-2511 |
| Chatterjee S, Richert L, Augustijns P, et al. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis[J]. Toxicology and Applied Pharmacology, 2014, 274(1):124-136 |
| Xu J J, Henstock P V, Dunn M C, et al. Cellular imaging predictions of clinical drug-induced liver injury[J]. Toxicological Sciences:An Official Journal of the Society of Toxicology, 2008, 105(1):97-105 |
| Zeigerer A, Wuttke A, Marsico G, et al. Functional properties of hepatocytes in vitro are correlated with cell polarity maintenance[J]. Experimental Cell Research, 2017, 350(1):242-252 |
| Yokoyama Y, Sasaki Y, Terasaki N, et al. Comparison of drug metabolism and its related hepatotoxic effects in HepaRG, cryopreserved human hepatocytes, and HepG2 cell cultures[J]. Biological&Pharmaceutical Bulletin, 2018, 41(5):722-732 |
| Sison-Young R L, Mitsa D, Jenkins R E, et al. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication[J]. Toxicological Sciences:An Official Journal of the Society of Toxicology, 2015, 147(2):412-424 |
| Ramaiahgari S C, Ferguson S S. Organotypic 3D HepaRG liver model for assessment of drug-induced cholestasis[J]. Methods in Molecular Biology, 2019, 1981:313-323 |
| Basharat A, Rollison H E, Williams D P, et al. HepG2(C3A) spheroids show higher sensitivity compared to HepaRG spheroids for drug-induced liver injury (DILI)[J]. Toxicology and Applied Pharmacology, 2020, 408:115279 |
| Gupta R, Schrooders Y, Hauser D, et al. Comparing in vitro human liver models to in vivo human liver using RNA-Seq[J]. Archives of Toxicology, 2021, 95(2):573-589 |
| van Grunsven L A. 3D in vitro models of liver fibrosis[J]. Advanced Drug Delivery Reviews, 2017, 121:133-146 |
| Prestigiacomo V, Weston A, Messner S, et al. Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis[J]. PLoS One, 2017, 12(6):e0179995 |
| Dash A, Simmers M B, Deering T G, et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro [J]. American Journal of Physiology Cell Physiology, 2013, 304(11):C1053-C1063 |
| Zeilinger K, Schreiter T, Darnell M, et al. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies[J]. Tissue Engineering Part C, Methods, 2011, 17(5):549-556 |
| Darnell M, Ulvestad M, Ellis E, et al. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system[J]. The Journal of Pharmacology and Experimental Therapeutics, 2012, 343(1):134-144 |
| Prill S, Bavli D, Levy G, et al. Real-time monitoring of oxygen uptake in hepatic bioreactor shows CYP450-independent mitochondrial toxicity of acetaminophen and amiodarone[J]. Archives of Toxicology, 2016, 90(5):1181-1191 |
| Mastrangeli M, Millet S, Orchid Partners T, et al. Organ-on-chip in development:Towards a roadmap for organs-on-chip[J]. ALTEX, 2019, 36(4):650-668 |
| 孙威,陈雨晴,罗国安,等.器官芯片及其应用[J].分析化学, 2016, 44(4):533-541 Sun W, Chen Y Q, Luo G A, et al. Organs-on-chips and its applications[J]. Chinese Journal of Analytical Chemistry, 2016, 44(4):533-541(in Chinese) |
| Ehrlich A, Duche D, Ouedraogo G, et al. Challenges and opportunities in the design of liver-on-chip microdevices[J]. Annual Review of Biomedical Engineering, 2019, 21:219-239 |
| Nguyen D G, Funk J, Robbins J B, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro [J]. PLoS One, 2016, 11(7):e0158674 |
| Rennert K, Steinborn S, Gr ger M, et al. A microfluidically perfused three dimensional human liver model[J]. Biomaterials, 2015, 71:119-131 |
| Cavero I, Guillon J M, Holzgrefe H H. Human organotypic bioconstructs from organ-on-chip devices for human-predictive biological insights on drug candidates[J]. Expert Opinion on Drug Safety, 2019, 18(8):651-677 |
| Murphy S V, Atala A. 3D bioprinting of tissues and organs[J]. Nature Biotechnology, 2014, 32(8):773-785 |
| Odde D J, Renn M J. Laser-guided direct writing for applications in biotechnology[J]. Trends in Biotechnology, 1999, 17(10):385-389 |
| Xu T, Jin J, Gregory C, et al. Inkjet printing of viable mammalian cells[J]. Biomaterials, 2005, 26(1):93-99 |
| Ozbolat I T, Hospodiuk M. Current advances and future perspectives in extrusion-based bioprinting[J]. Biomaterials, 2016, 76:321-343 |
| Gao B, Yang Q Z, Zhao X, et al. 4D bioprinting for biomedical applications[J]. Trends in Biotechnology, 2016, 34(9):746-756 |
| Jiang J, Pieterman C D, Ertaylan G, et al. The application of omics-based human liver platforms for investigating the mechanism of drug-induced hepatotoxicity in vitro [J]. Archives of Toxicology, 2019, 93(11):3067-3098 |
| Li L, Gokduman K, Gokaltun A, et al. A microfluidic 3D hepatocyte chip for hepatotoxicity testing of nanoparticles[J]. Nanomedicine, 2019, 14(16):2209-2226 |
| Jiang T Y, Guo H X, Xia Y N, et al. Hepatotoxicity of copper sulfide nanoparticles towards hepatocyte spheroids using a novel multi-concave agarose chip method[J]. Nanomedicine, 2021, 16(17):1487-1504 |
| Elje E, Mariussen E, Moriones O H, et al. Hepato (geno) toxicity assessment of nanoparticles in a HepG2 liver spheroid model[J]. Nanomaterials, 2020, 10(3):E545 |
| Yan L, Messner C J, Zhang X W, et al. Assessment of fibrotic pathways induced by environmental chemicals using 3D-human liver microtissue model[J]. Environmental Research, 2021, 194:110679 |
| Sharin T, Crump D, O'Brien J M. Evaluation of the aryl hydrocarbon receptor response in LMH 3D spheroids[J]. Environmental Toxicology and Chemistry, 2020, 39(9):1693-1701 |
| Goud E S K, Pandey M, Singh C, et al. Effect of dioxins in milk on the 3D cultured primary buffalo hepatocyte model system[J]. Journal of Agricultural and Food Chemistry, 2019, 67(28):8007-8019 |
| Sun S J, Guo H, Wang J S, et al. Hepatotoxicity of perfluorooctanoic acid and two emerging alternatives based on a 3D spheroid model[J]. Environmental Pollution, 2019, 246:955-962 |
| Kim B Y, Kim M, Jeong J S, et al. Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo [J]. Environmental Research, 2019, 173:124-134 |
| Jellali R, Jacques S, Essaouiba A, et al. Investigation of steatosis profiles induced by pesticides using liver organ-on-chip model and omics analysis[J]. Food and Chemical Toxicology, 2021, 152:112155 |
| Sharin T, Gyasi H, Jones S P, et al. Concentration-and time-dependent induction of Cyp1a and DNA damage response by benzo (a) pyrene in LMH three-dimensional spheroids[J]. Environmental and Molecular Mutagenesis, 2021, 62(5):319-327 |
| Mandon M, Huet S, Dubreil E, et al. Three-dimensional HepaRG spheroids as a liver model to study human genotoxicity in vitro with the single cell gel electrophoresis assay[J]. Scientific Reports, 2019, 9(1):10548 |
| Lee J, Choi B, da Yoon No, et al. A 3D alcoholic liver disease model on a chip[J]. Integrative Biology, 2016, 8(3):302-308 |
| Elder A, Vidyasagar S, DeLouise L. Physicochemical factors that affect metal and metal oxide nanoparticle passage across epithelial barriers[J]. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 2009, 1(4):434-450 |
| Meesters J A J, Quik J T K, Koelmans A A, et al. Multimedia environmental fate and speciation of engineered nanoparticles:A probabilistic modeling approach[J]. Environmental Science:Nano, 2016, 3(4):715-727 |
| Kaundal B, Dalai S, Choudhury S R. Nanomaterial Toxicity in Microbes, Plants and Animals[M]//Sustainable Agriculture Reviews. Cham:Springer International Publishing, 2017:243-266 |
| Lee J, Lilly G D, Doty R C, et al. In vitro toxicity testing of nanoparticles in 3D cell culture[J]. Small, 2009, 5(10):1213-1221 |
| Vezina C M, Walker N J, Olson J R. Subchronic exposure to TCDD, PeCDF, PCB126, and PCB153:Effect on hepatic gene expression[J]. Environmental Health Perspectives, 2004, 112(16):1636-1644 |
| Kovalova N, Nault R, Crawford R, et al. Comparative analysis of TCDD-induced AhR-mediated gene expression in human, mouse and rat primary B cells[J]. Toxicology and Applied Pharmacology, 2017, 316:95-106 |
| Li C Y, Liu Y Y, Dong Z, et al. TCDD promotes liver fibrosis through disordering systemic and hepatic iron homeostasis[J]. Journal of Hazardous Materials, 2020, 395:122588 |
| Yue S Q, Yu J, Kong Y, et al. Metabolomic modulations of HepG2 cells exposed to bisphenol analogues[J]. Environment International, 2019, 129:59-67 |
| Gijbels E, Vilas-Boas V, Annaert P, et al. Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury[J]. Archives of Toxicology, 2020, 94(4):1151-1172 |
| Dragovic S, Vermeulen N P, Gerets H H, et al. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man[J]. Archives of Toxicology, 2016, 90(12):2979-3003 |
| Tollefsen K E, Scholz S, Cronin M T, et al. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA)[J]. Regulatory Toxicology and Pharmacology, 2014, 70(3):629-640 |